The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Haemonetics Corp (NYSE: HAE) closed at $68.89 down -3.37% from its previous closing price of $71.29. In other words, the price has decreased by -$3.37 from its previous closing price. On the day, 1.45 million shares were traded. HAE stock price reached its highest trading level at $71.945 during the session, while it also had its lowest trading level at $68.65.
Ratios:
For a deeper understanding of Haemonetics Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 91.34. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 3.49. In the meantime, Its Debt-to-Equity ratio is 1.39 whereas as Long-Term Debt/Eq ratio is at 1.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on December 06, 2024, initiated with a Overweight rating and assigned the stock a target price of $116.
On November 08, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $120.
On September 13, 2024, CL King started tracking the stock assigning a Buy rating and target price of $116.CL King initiated its Buy rating on September 13, 2024, with a $116 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 11 ’24 when Lingamneni Anila bought 6,238 shares for $90.68 per share.
Strong Stewart W sold 4,312 shares of HAE for $393,039 on Jul 26 ’24. The President, Global Hospital now owns 18,196 shares after completing the transaction at $91.15 per share. On Jul 26 ’24, another insider, Strong Stewart W, who serves as the Officer of the company, bought 4,312 shares for $91.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3459924480 and an Enterprise Value of 4474864640. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.61, and their Forward P/E ratio for the next fiscal year is 13.06. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.54 while its Price-to-Book (P/B) ratio in mrq is 3.95. Its current Enterprise Value per Revenue stands at 3.287 whereas that against EBITDA is 14.244.
Stock Price History:
The Beta on a monthly basis for HAE is 0.40, which has changed by -0.099006 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $69.29. The 50-Day Moving Average of the stock is -14.52%, while the 200-Day Moving Average is calculated to be -16.27%.
Shares Statistics:
For the past three months, HAE has traded an average of 600.93K shares per day and 801400 over the past ten days. A total of 50.38M shares are outstanding, with a floating share count of 49.67M. Insiders hold about 1.11% of the company’s shares, while institutions hold 112.04% stake in the company. Shares short for HAE as of 1736899200 were 4959780 with a Short Ratio of 8.25, compared to 1734048000 on 4908199. Therefore, it implies a Short% of Shares Outstanding of 4959780 and a Short% of Float of 15.619999000000002.
